The latest price target for Haemonetics (NYSE:HAE) was reported by Raymond James on February 7, 2025. The analyst firm set a price target for $115.00 expecting HAE to rise to within 12 months (a possible 67.01% upside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for Haemonetics (NYSE:HAE) was provided by Raymond James, and Haemonetics reiterated their strong buy rating.

The last upgrade for Haemonetics Corp happened on November 8, 2024 when Raymond James raised their price target to $120. Raymond James previously had an outperform for Haemonetics Corp.

There is no last downgrade for Haemonetics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Haemonetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Haemonetics was filed on February 7, 2025 so you should expect the next rating to be made available sometime around February 7, 2026.

While ratings are subjective and will change, the latest Haemonetics (HAE) rating was a reiterated with a price target of $120.00 to $115.00. The current price Haemonetics (HAE) is trading at is $68.86, which is out of the analyst’s predicted range.